Cargando…

Ivabradine: the evidence of its therapeutic impact in angina

INTRODUCTION: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and increased use of healthcare resources. Ivabradine is a drug with a unique therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquis-Gravel, Guillaume, Tardif, Jean-Claude
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899802/
https://www.ncbi.nlm.nih.gov/pubmed/20694080
http://dx.doi.org/10.3355/ce.2008.008
_version_ 1782183562747838464
author Marquis-Gravel, Guillaume
Tardif, Jean-Claude
author_facet Marquis-Gravel, Guillaume
Tardif, Jean-Claude
author_sort Marquis-Gravel, Guillaume
collection PubMed
description INTRODUCTION: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and increased use of healthcare resources. Ivabradine is a drug with a unique therapeutic target, the I(f) current of the sinus node, developed for the treatment of cardiovascular diseases including SAP. It has an exclusive heart rate reducing effect, without any negative effect on left ventricular function or coronary vasodilatation. AIMS: The aim of this paper is to review the evidence concerning the use of ivabradine in the treatment of SAP. EVIDENCE REVIEW: Ivabradine is an effective antianginal and antiischemic drug, not inferior to the beta blocker atenolol and the calcium channel antagonist (CCA) amlodipine. It decreases the frequency of angina attacks and increases the time to anginal symptoms during exercise. Because of its exclusive chronotropic effect, ivabradine is not associated with the typical adverse reactions associated with beta blockers or other antianginal drugs. CLINICAL VALUE: Clinical evidence shows that ivabradine is a very good antiischemic and antianginal agent, being as effective as beta blockade and CCA therapy in controlling myocardial ischemia and symptoms of stable angina. Ongoing studies will determine the potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure.
format Text
id pubmed-2899802
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28998022010-08-05 Ivabradine: the evidence of its therapeutic impact in angina Marquis-Gravel, Guillaume Tardif, Jean-Claude Core Evid Clinical Impact Review INTRODUCTION: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and increased use of healthcare resources. Ivabradine is a drug with a unique therapeutic target, the I(f) current of the sinus node, developed for the treatment of cardiovascular diseases including SAP. It has an exclusive heart rate reducing effect, without any negative effect on left ventricular function or coronary vasodilatation. AIMS: The aim of this paper is to review the evidence concerning the use of ivabradine in the treatment of SAP. EVIDENCE REVIEW: Ivabradine is an effective antianginal and antiischemic drug, not inferior to the beta blocker atenolol and the calcium channel antagonist (CCA) amlodipine. It decreases the frequency of angina attacks and increases the time to anginal symptoms during exercise. Because of its exclusive chronotropic effect, ivabradine is not associated with the typical adverse reactions associated with beta blockers or other antianginal drugs. CLINICAL VALUE: Clinical evidence shows that ivabradine is a very good antiischemic and antianginal agent, being as effective as beta blockade and CCA therapy in controlling myocardial ischemia and symptoms of stable angina. Ongoing studies will determine the potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure. Dove Medical Press 2008-06 2008-06 /pmc/articles/PMC2899802/ /pubmed/20694080 http://dx.doi.org/10.3355/ce.2008.008 Text en © 2008 Core Medical Publishing Limited
spellingShingle Clinical Impact Review
Marquis-Gravel, Guillaume
Tardif, Jean-Claude
Ivabradine: the evidence of its therapeutic impact in angina
title Ivabradine: the evidence of its therapeutic impact in angina
title_full Ivabradine: the evidence of its therapeutic impact in angina
title_fullStr Ivabradine: the evidence of its therapeutic impact in angina
title_full_unstemmed Ivabradine: the evidence of its therapeutic impact in angina
title_short Ivabradine: the evidence of its therapeutic impact in angina
title_sort ivabradine: the evidence of its therapeutic impact in angina
topic Clinical Impact Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899802/
https://www.ncbi.nlm.nih.gov/pubmed/20694080
http://dx.doi.org/10.3355/ce.2008.008
work_keys_str_mv AT marquisgravelguillaume ivabradinetheevidenceofitstherapeuticimpactinangina
AT tardifjeanclaude ivabradinetheevidenceofitstherapeuticimpactinangina